Heterogeneities in Cell Cycle Checkpoint Activation Following Doxorubicin Treatment Reveal Targetable Vulnerabilities in TP53 Mutated Ultra High-Risk Neuroblastoma Cell Lines

por Ödborn Jönsson, Linnéa, Sahi, Maryam, Lopez-Lorenzo, Ximena, Keller, Faye Leilah, Kostopoulou, Ourania N., Herold, Nikolas, Ährlund-Richter, Lars, Shirazi Fard, Shahrzad
Publicado 2021